VYNE Therapeutics Ownership 2024 | Who Owns VYNE Therapeutics Now?
Institutional Ownership
0.09%
Insider Ownership
8.33%
Retail Ownership
91.59%
Institutional Holders
2.00
VYNE Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| STALEY CAPITAL ADVISERS INC | 0.09% | 0.00% | 36,472 | - | - | 71,850 | Jun 30, 2024 |
| ASHTON THOMAS PRIVATE WEALTH, LLC | - | - | 19 | 19 | 100.00% | 37 | Jun 30, 2024 |
| CORNERSTONE PLANNING GROUP LLC | - | - | - | -2 | -100.00% | - | Jun 30, 2024 |
VYNE Therapeutics's largest institutional shareholder is STALEY CAPITAL ADVISERS INC, holding 0.09% of the company's total share outstanding, currently valued at $71.85K. The top 10 institutional shareholders own together 0.09% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| STALEY CAPITAL ADVISERS INC | 0.09% | 0.00% | 36,472 | - | - | 71,850 | Jun 30, 2024 |
| ASHTON THOMAS PRIVATE WEALTH, LLC | - | - | 19 | 19 | 100.00% | 37 | Jun 30, 2024 |
| CORNERSTONE PLANNING GROUP LLC | - | - | - | -2 | -100.00% | - | Jun 30, 2024 |
The largest VYNE Therapeutics shareholder by % of total assets is STALEY CAPITAL ADVISERS INC. The company owns 36.47K shares of VYNE Therapeutics (VYNE), representing 0.00% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ASHTON THOMAS PRIVATE WEALTH, LLC | - | - | 19 | 19 | 100.00% | 37 | Jun 30, 2024 |
| STALEY CAPITAL ADVISERS INC | 0.09% | 0.00% | 36,472 | - | - | 71,850 | Jun 30, 2024 |
| CORNERSTONE PLANNING GROUP LLC | - | - | - | -2 | -100.00% | - | Jun 30, 2024 |
As of Jun 30 2024, VYNE Therapeutics's largest institutional buyer is ASHTON THOMAS PRIVATE WEALTH, LLC. The company purchased 19.00 stocks of VYNE, valued at $37.00.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| CORNERSTONE PLANNING GROUP LLC | - | - | - | -2 | -100.00% | - | Jun 30, 2024 |
| STALEY CAPITAL ADVISERS INC | 0.09% | 0.00% | 36,472 | - | - | 71,850 | Jun 30, 2024 |
| ASHTON THOMAS PRIVATE WEALTH, LLC | - | - | 19 | 19 | 100.00% | 37 | Jun 30, 2024 |
As of Jun 30 2024, VYNE Therapeutics's biggest institutional seller is CORNERSTONE PLANNING GROUP LLC. The company sold -2.00 shares of VYNE, valued at -.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ASHTON THOMAS PRIVATE WEALTH, LLC | - | - | 19 | 19 | 100.00% | 37 | Jun 30, 2024 |
VYNE Therapeutics's largest new institutional shareholder by number of shares is ASHTON THOMAS PRIVATE WEALTH, LLC, purchased 19.00 shares, valued at $37.00, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| CORNERSTONE PLANNING GROUP LLC | - | - | - | -2 | -100.00% | - | Jun 30, 2024 |
VYNE Therapeutics's largest sold out institutional shareholder by shares sold is CORNERSTONE PLANNING GROUP LLC, sold -2.00 shares, valued at -, as of undefined.
VYNE Therapeutics Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| TEKLA HEALTHCARE INVESTORS | 0.44% | 379,103 | - | - | Mar 31, 2024 |
| TEKLA LIFE SCIENCES INVESTORS | 0.34% | 162,481 | - | - | Mar 31, 2024 |
| FRANKLIN STRATEGIC SERIES | 0.34% | 2,882,600 | - | - | Jan 31, 2024 |
| TEKLA HEALTHCARE INVESTORS | 0.11% | 94,775 | - | - | Mar 31, 2024 |
| Listed Funds Trust | 0.10% | 490,430 | - | - | Mar 31, 2024 |
| TEKLA LIFE SCIENCES INVESTORS | 0.09% | 40,620 | - | - | Mar 31, 2024 |
| FRANKLIN STRATEGIC SERIES | 0.08% | 720,650 | - | - | Jan 31, 2024 |
| DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.04% | 24,004 | - | - | Mar 31, 2024 |
| QUANTITATIVE MASTER SERIES LLC | 0.04% | 238,882 | - | - | Mar 31, 2024 |
| VANGUARD INDEX FUNDS | 0.02% | 6,749,682 | - | - | Mar 31, 2024 |
| NEXPOINT FUNDS I | 0.01% | 40,205 | - | - | Dec 31, 2023 |
| DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.01% | 6,001 | - | - | Mar 31, 2024 |
| QUANTITATIVE MASTER SERIES LLC | 0.01% | 53,915 | - | - | Mar 31, 2024 |
| SCHWAB CAPITAL TRUST | 0.01% | 357,565 | - | - | Feb 29, 2024 |
| TIAA SEPARATE ACCOUNT VA 1 | 0.01% | 1,875 | - | - | Mar 31, 2024 |
| TEKLA HEALTHCARE INVESTORS | 0.01% | 5,265 | - | - | Mar 31, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.01% | 1,119,021 | - | - | Feb 29, 2024 |
| TEKLA LIFE SCIENCES INVESTORS | 0.00% | 2,255 | - | - | Mar 31, 2024 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 140,392 | - | - | Mar 31, 2024 |
| VANGUARD INDEX FUNDS | 0.00% | 1,632,535 | - | - | Mar 31, 2024 |
| Calvert Variable Products, Inc. | 0.00% | 9,411 | - | - | Mar 31, 2024 |
| SunAmerica Specialty Series | 0.00% | 1,197 | - | - | Apr 30, 2021 |
| TIAA SEPARATE ACCOUNT VA 1 | 0.00% | 468 | - | - | Mar 31, 2024 |
| Voya VARIABLE PORTFOLIOS INC | 0.00% | 66,171 | - | - | Mar 31, 2024 |
| JPMORGAN INSURANCE TRUST | 0.00% | 26,800 | - | - | Mar 31, 2023 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 423,979 | - | - | Feb 29, 2024 |
| Columbia Funds Variable Series Trust II | 0.00% | 63,065 | - | - | Mar 31, 2024 |
| VANGUARD VARIABLE INSURANCE FUNDS | 0.00% | 76,105 | - | - | Mar 31, 2024 |
| NATIONWIDE VARIABLE INSURANCE TRUST | 0.00% | 159,936 | - | - | Mar 31, 2024 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 35,098 | - | - | Mar 31, 2024 |
| Calvert Variable Products, Inc. | 0.00% | 3,067 | - | - | Mar 31, 2024 |
| T. Rowe Price Index Trust, Inc. | 0.00% | 20,850 | - | - | Feb 29, 2024 |
| Principal Exchange-Traded Funds | 0.00% | 10,198 | - | - | Mar 31, 2024 |
| FLEXSHARES TRUST | 0.00% | 64,076 | - | - | Jan 31, 2024 |
| Voya INVESTORS TRUST | 0.00% | 39,300 | - | - | Mar 31, 2024 |
| NORTHERN FUNDS | 0.00% | 79,032 | - | - | Mar 28, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 104,633 | 76,300 | 269.30% | Feb 29, 2024 |
| Voya VARIABLE PORTFOLIOS INC | 0.00% | 16,034 | - | - | Mar 31, 2024 |
| SCHWAB CAPITAL TRUST | 0.00% | 20,154 | - | - | Feb 29, 2024 |
| JPMORGAN INSURANCE TRUST | 0.00% | 5,800 | - | - | Mar 31, 2023 |
| BRIDGEWAY FUNDS INC | 0.00% | 1,025 | - | - | Mar 28, 2024 |
| EQ ADVISORS TRUST | 0.00% | 454,622 | - | - | Mar 31, 2024 |
| STATE STREET INSTITUTIONAL INVESTMENT TRUST | 0.00% | 22,793 | - | - | Mar 31, 2024 |
| THRIVENT SERIES FUND INC | 0.00% | 34,446 | - | - | Mar 28, 2024 |
| COLLEGE RETIREMENT EQUITIES FUND | 0.00% | 267,434 | - | - | Mar 31, 2024 |
| FIDELITY SALEM STREET TRUST | 0.00% | 970,951 | - | - | Mar 31, 2024 |
| VALIC Co I | 0.00% | 69,416 | - | - | Feb 29, 2024 |
| ProFunds | 0.00% | 2,451 | - | - | Mar 31, 2024 |
| THRIVENT MUTUAL FUNDS | 0.00% | 18,741 | - | - | Mar 28, 2024 |
| ETF Series Solutions | 0.00% | 3,850 | - | - | Jan 31, 2024 |
| SEASONS SERIES TRUST | 0.00% | 4,275 | - | - | Mar 31, 2024 |
| PACE SELECT ADVISORS TRUST | 0.00% | 56,485 | - | - | Jan 31, 2024 |
| Voya INVESTORS TRUST | 0.00% | 9,124 | - | - | Mar 31, 2024 |
| VANGUARD INDEX FUNDS | 0.00% | 68,629 | -28,527 | -29.36% | Mar 31, 2024 |
| VARIABLE INSURANCE PRODUCTS FUND II | 0.00% | 1,865 | - | - | Mar 31, 2024 |
| PENN SERIES FUNDS INC | 0.00% | 4,200 | - | - | Mar 28, 2024 |
| VANGUARD SCOTTSDALE FUNDS | 0.00% | 281,517 | - | - | Feb 29, 2024 |
| NORTHERN FUNDS | 0.00% | 19,758 | - | - | Mar 28, 2024 |
| NATIONWIDE MUTUAL FUNDS | 0.00% | 17,061 | - | - | Jan 31, 2024 |
| RUSSELL INVESTMENT CO | 0.00% | 37,577 | - | - | Jan 31, 2024 |
| TIAA-CREF FUNDS | 0.00% | 347,417 | - | - | Mar 31, 2024 |
| STATE STREET INSTITUTIONAL INVESTMENT TRUST | 0.00% | 6,822 | - | - | Mar 31, 2024 |
| MUTUAL FUND SERIES TRUST | 0.00% | 445,000 | -223,151 | -33.40% | Mar 31, 2024 |
| USAA MUTUAL FUNDS TRUST | 0.00% | 22,780 | - | - | Jan 31, 2024 |
| MORGAN STANLEY PATHWAY FUNDS | 0.00% | 9,394 | - | - | Feb 29, 2024 |
| Brighthouse Funds Trust II | 0.00% | 71,462 | - | - | Mar 31, 2024 |
| MASTER INVESTMENT PORTFOLIO | 0.00% | 6,748 | - | - | Mar 31, 2024 |
| VANGUARD QUANTITATIVE FUNDS | 0.00% | 339 | - | - | Mar 31, 2024 |
| ProFunds | 0.00% | 787 | - | - | Mar 31, 2024 |
| FIDELITY SALEM STREET TRUST | 0.00% | 270,973 | - | - | Mar 31, 2024 |
| LINCOLN VARIABLE INSURANCE PRODUCTS TRUST | 0.00% | 167,784 | - | - | Mar 31, 2024 |
| VALIC Co I | 0.00% | 17,231 | - | - | Feb 29, 2024 |
| COLLEGE RETIREMENT EQUITIES FUND | 0.00% | 60,443 | - | - | Mar 31, 2024 |
| RUSSELL INVESTMENT FUNDS | 0.00% | 6,347 | - | - | Mar 31, 2024 |
| ETF Series Solutions | 0.00% | 1,185 | - | - | Jan 31, 2024 |
| LINCOLN VARIABLE INSURANCE PRODUCTS TRUST | 0.00% | 134,000 | - | - | Mar 31, 2024 |
| VANGUARD SCOTTSDALE FUNDS | 0.00% | 108,190 | - | - | Feb 29, 2024 |
| NATIONWIDE VARIABLE INSURANCE TRUST | 0.00% | 6,259 | - | - | Mar 31, 2024 |
| SUNAMERICA SERIES TRUST | 0.00% | 15,985 | - | - | Mar 31, 2024 |
| PROSHARES TRUST | 0.00% | 9,389 | - | - | Feb 29, 2024 |
| TIAA-CREF LIFE FUNDS | 0.00% | 98 | - | - | Mar 31, 2024 |
| PENN SERIES FUNDS INC | 0.00% | 1,050 | - | - | Mar 28, 2024 |
| SEASONS SERIES TRUST | 0.00% | 843 | - | - | Mar 31, 2024 |
| VANGUARD WELLINGTON FUND | 0.00% | 14,098 | - | - | Feb 29, 2024 |
| JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 68,789 | - | - | Mar 31, 2024 |
| TIAA-CREF FUNDS | 0.00% | 86,011 | - | - | Mar 31, 2024 |
| USAA MUTUAL FUNDS TRUST | 0.00% | 6,515 | - | - | Jan 31, 2024 |
| MORGAN STANLEY PATHWAY FUNDS | 0.00% | 2,348 | - | - | Feb 29, 2024 |
| T. Rowe Price Index Trust, Inc. | 0.00% | 413 | - | - | Feb 29, 2024 |
| PACIFIC SELECT FUND | 0.00% | 66,129 | - | - | Mar 31, 2024 |
| MASSMUTUAL SELECT FUNDS | 0.00% | 18,606 | - | - | Dec 31, 2023 |
| VANGUARD QUANTITATIVE FUNDS | 0.00% | 84 | - | - | Mar 31, 2024 |
| Legg Mason Global Asset Management Trust | 0.00% | 93,534 | - | - | Jan 31, 2024 |
| Bridge Builder Trust | 0.00% | 55,535 | - | - | Mar 31, 2024 |
| THRIVENT SERIES FUND INC | 0.00% | 1,258 | - | - | Mar 28, 2024 |
| THRIVENT MUTUAL FUNDS | 0.00% | 1,038 | - | - | Mar 28, 2024 |
| TIAA-CREF LIFE FUNDS | 0.00% | 24 | - | - | Mar 31, 2024 |
| EQ ADVISORS TRUST | 0.00% | 9,502 | - | - | Mar 31, 2024 |
| DFA INVESTMENT DIMENSIONS GROUP INC | 0.00% | 7,746 | 3,873 | 100.00% | Jan 31, 2024 |
| SUNAMERICA SERIES TRUST | 0.00% | 2,600 | - | - | Mar 31, 2024 |
VYNE Therapeutics's largest mutual fund holder by % of total assets is "TEKLA HEALTHCARE INVESTORS", owning 379.10K shares, compromising 0.44% of its total assets.
VYNE Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 24 | 2 | - |
| 31 Mar, 24 | 2 | 100.00% |
| 31 Dec, 23 | 1 | - |
| 30 Sep, 23 | 1 | - |
| 30 Jun, 23 | 1 | - |
| 31 Mar, 23 | 1 | -97.30% |
| 31 Dec, 22 | 37 | 27.59% |
| 30 Sep, 22 | 29 | -12.12% |
| 30 Jun, 22 | 33 | -19.51% |
| 31 Mar, 22 | 41 | -19.61% |
| 31 Dec, 21 | 51 | -15.00% |
| 30 Sep, 21 | 60 | -10.45% |
| 30 Jun, 21 | 67 | -21.18% |
| 31 Mar, 21 | 85 | - |
As of 30 Jun 24, 2 institutions are holding VYNE Therapeutics's shares, representing an increase of 0.00% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 24 | 36,491 | 0.05% |
| 31 Mar, 24 | 36,474 | 0.01% |
| 31 Dec, 23 | 36,472 | 55.39% |
| 30 Sep, 23 | 23,472 | - |
| 30 Jun, 23 | 23,472 | - |
| 31 Mar, 23 | 23,472 | -99.68% |
| 31 Dec, 22 | 7,315,959 | -11.28% |
| 30 Sep, 22 | 8,246,275 | -1.42% |
| 30 Jun, 22 | 8,364,687 | -3.38% |
| 31 Mar, 22 | 8,657,555 | -29.34% |
| 31 Dec, 21 | 12,252,387 | -15.31% |
| 30 Sep, 21 | 14,467,413 | -20.63% |
| 30 Jun, 21 | 18,226,976 | -18.09% |
| 31 Mar, 21 | 22,252,314 | - |
VYNE Therapeutics (VYNE) has 36.49K shares outstanding as of 30 Jun 24, up 0.05% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 24 | 0.09% | 68.00% |
| 31 Mar, 24 | 0.35% | 28.75% |
| 31 Dec, 23 | 1.11% | 216.22% |
| 30 Sep, 23 | 0.72% | 137.87% |
| 30 Jun, 23 | 0.72% | 138.68% |
| 31 Mar, 23 | 0.72% | 0.44% |
| 31 Dec, 22 | 12.76% | 6.30% |
| 30 Sep, 22 | 14.23% | 6.83% |
| 30 Jun, 22 | 14.44% | 5.91% |
| 31 Mar, 22 | 15.63% | 2.76% |
| 31 Dec, 21 | 23.81% | 3.08% |
| 30 Sep, 21 | 27.81% | 2.21% |
| 30 Jun, 21 | 35.45% | 1.71% |
| 31 Mar, 21 | 45.54% | - |
As of 30 Jun 24, VYNE Therapeutics is held by 0.09% institutional shareholders, representing a 68.00% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 1 | - |
| 31 Mar, 24 | 1 | - |
| 31 Dec, 23 | 1 | - |
| 30 Sep, 23 | - | - |
| 30 Jun, 23 | - | - |
| 31 Mar, 23 | - | -100.00% |
| 31 Dec, 22 | 12 | 50.00% |
| 30 Sep, 22 | 8 | -20.00% |
| 30 Jun, 22 | 10 | -23.08% |
| 31 Mar, 22 | 13 | -35.00% |
| 31 Dec, 21 | 20 | -13.04% |
| 30 Sep, 21 | 23 | -25.81% |
| 30 Jun, 21 | 31 | -63.10% |
| 31 Mar, 21 | 84 | - |
1 institutional shareholders have increased their position in VYNE stock as of 30 Jun 24 compared to 1 in the previous quarter (a 0.00% increase).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 24 | - | - |
| 31 Mar, 24 | - | - |
| 31 Dec, 23 | - | - |
| 30 Sep, 23 | - | - |
| 30 Jun, 23 | - | -100.00% |
| 31 Mar, 23 | 1 | -91.67% |
| 31 Dec, 22 | 12 | 71.43% |
| 30 Sep, 22 | 7 | -36.36% |
| 30 Jun, 22 | 11 | -15.38% |
| 31 Mar, 22 | 13 | -7.14% |
| 31 Dec, 21 | 14 | -33.33% |
| 30 Sep, 21 | 21 | -8.70% |
| 30 Jun, 21 | 23 | - |
| 31 Mar, 21 | - | - |
- institutional shareholders have reduced their position in VYNE stock as of 30 Jun 24 compared to - in the previous quarter (a 0.00% increase).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 24 | 2 | - | 36,491 | 0.05% | 0.09% | 68.00% | 1 | - | - | - |
| 31 Mar, 24 | 2 | 100.00% | 36,474 | 0.01% | 0.35% | 28.75% | 1 | - | - | - |
| 31 Dec, 23 | 1 | - | 36,472 | 55.39% | 1.11% | 216.22% | 1 | - | - | - |
| 30 Sep, 23 | 1 | - | 23,472 | - | 0.72% | 137.87% | - | - | - | - |
| 30 Jun, 23 | 1 | - | 23,472 | - | 0.72% | 138.68% | - | - | - | -100.00% |
| 31 Mar, 23 | 1 | -97.30% | 23,472 | -99.68% | 0.72% | 0.44% | - | -100.00% | 1 | -91.67% |
| 31 Dec, 22 | 37 | 27.59% | 7,315,959 | -11.28% | 12.76% | 6.30% | 12 | 50.00% | 12 | 71.43% |
| 30 Sep, 22 | 29 | -12.12% | 8,246,275 | -1.42% | 14.23% | 6.83% | 8 | -20.00% | 7 | -36.36% |
| 30 Jun, 22 | 33 | -19.51% | 8,364,687 | -3.38% | 14.44% | 5.91% | 10 | -23.08% | 11 | -15.38% |
| 31 Mar, 22 | 41 | -19.61% | 8,657,555 | -29.34% | 15.63% | 2.76% | 13 | -35.00% | 13 | -7.14% |
| 31 Dec, 21 | 51 | -15.00% | 12,252,387 | -15.31% | 23.81% | 3.08% | 20 | -13.04% | 14 | -33.33% |
| 30 Sep, 21 | 60 | -10.45% | 14,467,413 | -20.63% | 27.81% | 2.21% | 23 | -25.81% | 21 | -8.70% |
| 30 Jun, 21 | 67 | -21.18% | 18,226,976 | -18.09% | 35.45% | 1.71% | 31 | -63.10% | 23 | - |
| 31 Mar, 21 | 85 | - | 22,252,314 | - | 45.54% | - | 84 | - | - | - |
VYNE Therapeutics Insider Shareholders Trades
Open Market Insider Trades
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Open Market Insider Buys
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Insider Sells
All Insider Owners Trades
The last insider sell of VYNE Therapeutics's stock was made by Zeronda Tyler on Jul 03 2024, selling 92 shares at $1.92 per share (valued at $176.64).
VYNE Therapeutics Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q3 2024 | - | 4 | - |
| Q2 2024 | 1 | 4 | 25.00% |
| Q1 2024 | 14 | 4 | 350.00% |
| Q4 2023 | 15 | 6 | 250.00% |
| Q2 2023 | 2 | 4 | 50.00% |
| Q1 2023 | 2 | 4 | 50.00% |
| Q4 2022 | 1 | 4 | 25.00% |
| Q3 2022 | 9 | 4 | 225.00% |
| Q2 2022 | 2 | 4 | 50.00% |
| Q1 2022 | 9 | 4 | 225.00% |
| Q4 2021 | 3 | 4 | 75.00% |
| Q3 2021 | 15 | 7 | 214.29% |
| Q2 2021 | 3 | 11 | 27.27% |
| Q1 2021 | 12 | 5 | 240.00% |
| Q4 2020 | 4 | 4 | 100.00% |
| Q3 2020 | 9 | 5 | 180.00% |
| Q2 2020 | 25 | 8 | 312.50% |
| Q1 2020 | 60 | 13 | 461.54% |
| Q4 2019 | 9 | 14 | 64.29% |
| Q3 2019 | 7 | - | - |
0 total buy trades, and 4 total sell trades (buy/sell ratio of 0.00%) were made by VYNE Therapeutics's insiders, as of Q3 2024.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q3 2024 | - | - | - |
| Q2 2024 | - | - | - |
| Q1 2024 | - | - | - |
| Q4 2023 | 1 | - | - |
| Q2 2023 | - | - | - |
| Q1 2023 | 2 | - | - |
| Q4 2022 | - | - | - |
| Q3 2022 | - | - | - |
| Q2 2022 | - | - | - |
| Q1 2022 | - | - | - |
| Q4 2021 | 1 | - | - |
| Q3 2021 | 1 | 3 | 33.33% |
| Q2 2021 | 1 | 1 | 100.00% |
| Q1 2021 | 2 | - | - |
| Q4 2020 | 1 | - | - |
| Q3 2020 | 2 | - | - |
| Q2 2020 | 1 | - | - |
| Q1 2020 | - | - | - |
| Q4 2019 | - | - | - |
| Q3 2019 | - | - | - |
As of Q3 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of VYNE Therapeutics's stocks.
VYNE Therapeutics Peer Ownership
| Ticker | Company |
|---|---|
| ZVSA | ZyVersa Therapeutics, Inc. |
| GOVX | GeoVax Labs, Inc. |
| MGTA | Dianthus Therapeutics, Inc. |
| VCYT | Veracyte, Inc. |
| AXLA | Axcella Health Inc. |
| PULM | Pulmatrix, Inc. |
| HSTO | Histogen Inc. |
| SABS | SAB Biotherapeutics, Inc. |
| PHIO | Phio Pharmaceuticals Corp. |
| LGVN | Longeveron Inc. |
| REVB | Revelation Biosciences, Inc. |
| RNAZ | TransCode Therapeutics, Inc. |
| BCEL | Atreca, Inc. |
| FWBI | Entero Therapeutics, Inc. |
| AKTX | Akari Therapeutics, Plc |
| KRON | Kronos Bio, Inc. |
| VCNX | Vaccinex, Inc. |
| UNCY | Unicycive Therapeutics, Inc. |
| SLRX | Salarius Pharmaceuticals, Inc. |
| CDTX | Cidara Therapeutics, Inc. |
| LYRA | Lyra Therapeutics, Inc. |
| CBIO | Gyre Therapeutics, Inc. |
| ZURA | Zura Bio Limited |
VYNE Ownership FAQ
Who Owns VYNE Therapeutics?
VYNE Therapeutics is owned by institutional shareholders (0.09%), insiders (8.33%), and public (91.59%). The largest institutional shareholder of VYNE Therapeutics is STALEY CAPITAL ADVISERS INC (0.09% of total shares) and the top mutual fund owner is TEKLA HEALTHCARE INVESTORS (0.44% of total shares).
Who are the major institutional shareholders of VYNE Therapeutics?
VYNE Therapeutics's major institutional shareholders are STALEY CAPITAL ADVISERS INC, ASHTON THOMAS PRIVATE WEALTH, LLC, and CORNERSTONE PLANNING GROUP LLC. The top five shareholders own together 0.09% of the company's share outstanding.
How many VYNE Therapeutics shareholders are there?
As of Jun 2024, there are 2 institutional shareholders of VYNE Therapeutics.
What percentage of VYNE Therapeutics is owned by STALEY CAPITAL ADVISERS INC?
STALEY CAPITAL ADVISERS INC owns 36.47K shares of VYNE Therapeutics, representing 0.09% of the company's total shares outstanding, valued at $71.85K (as of Jun 2024).
What percentage of VYNE Therapeutics is owned by ASHTON THOMAS PRIVATE WEALTH, LLC?
As of Jun 2024, ASHTON THOMAS PRIVATE WEALTH, LLC holds 19 shares of VYNE Therapeutics (VYNE), compromising 0% of the company, valued at $37.
What percentage of VYNE Therapeutics is owned by CORNERSTONE PLANNING GROUP LLC?
CORNERSTONE PLANNING GROUP LLC is the third largest holder of VYNE Therapeutics. The company owns 0 of the company's shares outstanding (worth $0).